Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

MRK

Merck (MRK)

Merck and Co Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:MRK
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202413h05PR Newswire (Canada)Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapyNYSE:MRKMerck and Co Inc
09/05/202413h05PR Newswire (Canada)Santé Canada approuve KEYTRUDA® pour le traitement, en association avec une chimiothérapie à base de gemcitabine, des adultes atteints d'un carcinome des voies biliaires non résécable localement avancé ou métastatiqueNYSE:MRKMerck and Co Inc
09/05/202412h45Business WireMerck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative IntentNYSE:MRKMerck and Co Inc
08/05/202412h45Business WireMerck to Participate in the Bank of America Securities 2024 Healthcare ConferenceNYSE:MRKMerck and Co Inc
06/05/202422h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:MRKMerck and Co Inc
06/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
06/05/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
06/05/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
06/05/202422h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
01/05/202413h15Business WireMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaNYSE:MRKMerck and Co Inc
29/04/202415h00Business WireMerck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for AdultsNYSE:MRKMerck and Co Inc
25/04/202422h40IH Market NewsU.S. Stocks Climb Well Off Worst Levels But Close Mostly LowerNYSE:MRKMerck and Co Inc
25/04/202415h09IH Market NewsFutures Pointing To Sharply Lower Open On Wall StreetNYSE:MRKMerck and Co Inc
25/04/202413h52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNYSE:MRKMerck and Co Inc
25/04/202412h30Business WireMerck Announces First-Quarter 2024 Financial ResultsNYSE:MRKMerck and Co Inc
19/04/202413h04PR Newswire (Canada)Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-contaNYSE:MRKMerck and Co Inc
19/04/202413h04PR Newswire (Canada)Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) HNYSE:MRKMerck and Co Inc
10/04/202413h13IH Market NewsDelta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More NewsNYSE:MRKMerck and Co Inc
04/04/202412h45Business WireMerck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung CancerNYSE:MRKMerck and Co Inc
03/04/202414h00Business WireREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian CancerNYSE:MRKMerck and Co Inc
01/04/202412h45Business WireMerck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25NYSE:MRKMerck and Co Inc
28/03/202411h45Business WireEuropean Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in AdultsNYSE:MRKMerck and Co Inc
27/03/202411h54IH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNYSE:MRKMerck and Co Inc
26/03/202423h21Business WireFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)NYSE:MRKMerck and Co Inc
21/03/202411h45Business WireMerck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung CancerNYSE:MRKMerck and Co Inc
19/03/202414h00Business WireMerck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in AdultsNYSE:MRKMerck and Co Inc
15/03/202421h23PR Newswire (US)FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring PlatformNYSE:MRKMerck and Co Inc
15/03/202411h45Business WireMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical CancerNYSE:MRKMerck and Co Inc
13/03/202408h00Business WireMerck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9NYSE:MRKMerck and Co Inc
11/03/202413h15Business WireMerck Completes Acquisition of Harpoon Therapeutics, Inc.NYSE:MRKMerck and Co Inc
 Showing the most relevant articles for your search:NYSE:MRK